Generic implant receives positive ERP result

The first generic two-rod sub-dermal levonorgestrel 75mg implant product has received a positive result from the WHO Expert Review Panel (ERP). This makes it the first of its kind to reach the quality standard for international procurement. The product, manufactured by Shanghai Dahua Pharmaceutical in China, is marketed under global brand name Levoplant, and is currently undergoing review for WHO Prequalification.

This further expands the choice of affordable, high quality products that are available for procurement to lower and middle income countries, and will potentially result in increased access to contraceptive implants.

, , ,
Menu